HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Krystal Biotech (NASDAQ:KRYS), maintaining a $200 price target on the stock.

May 06, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech's stock maintains a Buy rating and a $200 price target from HC Wainwright & Co., indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future prospects and financial health. This endorsement can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100